100 related articles for article (PubMed ID: 3673162)
1. [Electrophysiologic and hemodynamic effects of the new anti-arrhythmia agent diprafenone].
Gülker H; Heuer H; Thale J; Behrenbeck T
Z Kardiol; 1987 Jul; 76(7):411-4. PubMed ID: 3673162
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the antiarrhythmic profile of the new class I agent diprafenone.
Gülker H; Thale J; Olbing B; Heuer H; Frenking B; Bender F
Arzneimittelforschung; 1985; 35(9):1387-93. PubMed ID: 4084340
[TBL] [Abstract][Full Text] [Related]
3. [Diprafenone--comparative study of anti-arrhythmia therapy with propafenone].
Geibel A; Zehender M; Hohnloser S; Landsrath C; Meinertz T; Just H
Z Kardiol; 1988 Jul; 77(7):464-9. PubMed ID: 2463720
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the electrophysiologic, antiarrhythmic and haemodynamic profile of a new isoquinolinedione derivative.
Gülker H; Spyra W; Thale J; Krimphove F; Hübner A; Bender F
Arzneimittelforschung; 1987 Aug; 37(8):917-9. PubMed ID: 3675686
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of chronic ventricular arrhythmias with the new class Ic anti-arrhythmia agent diprafenon--results of long-term therapy].
Heuer H; Gülker H; Hasfeld M; Frenking B; Behrenbeck T
Z Kardiol; 1987 Jul; 76(7):415-20. PubMed ID: 3673163
[TBL] [Abstract][Full Text] [Related]
6. Electrophysiologic, haemodynamic and antiarrhythmic effects of the new class Ic agent 1-(2'-biphenyloxy)-2-tert.-butylamino-propanol-2-hydrochloride.
Chiladakis I; Hindricks G; Haverkamp W; Vogt J; Gülker H
Arzneimittelforschung; 1989 Sep; 39(9):1130-2. PubMed ID: 2590263
[TBL] [Abstract][Full Text] [Related]
7. Beta-adrenoceptor blocking activity of diprafenone in anesthetized dogs: comparison with propafenone and propranolol.
Greenberg S; Cantor E; Paul J
J Cardiovasc Pharmacol; 1989 Sep; 14(3):444-53. PubMed ID: 2476625
[TBL] [Abstract][Full Text] [Related]
8. [Electrophysiologic effects of diprafenone in supraventricular and ventricular tachycardia].
Manz M; Beermann J; Gerckens U; Lüderitz B
Z Kardiol; 1986 Dec; 75(12):757-63. PubMed ID: 3825226
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiologic effects of asocainol, a new antiarrhythmic agent with predominant class I action.
Thale J; Gülker H; Hagemense B; Rose D; Haverkamp W; Frenking B
Arzneimittelforschung; 1987 Jan; 37(1):14-6. PubMed ID: 3566851
[TBL] [Abstract][Full Text] [Related]
10. N-(2,6-dimethylphenyl)-8-pyrrolizidineacetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent: effects on cardiac conduction.
Hidaka T; Hamasaki S; Aisaka K; Ishihara T; Morita M; Toyama J; Yamada K
Arzneimittelforschung; 1985; 35(9):1381-6. PubMed ID: 4084339
[TBL] [Abstract][Full Text] [Related]
11. Influence of the new class I antiarrhythmic agent diprafenone on the end-systolic pressure-volume relationship (conductance technique).
Thormann J; Kramer W; Kremer P; Schlepper M
Cardiovasc Drugs Ther; 1989 Apr; 3(2):145-54. PubMed ID: 2487530
[TBL] [Abstract][Full Text] [Related]
12. [Electrophysiologic effects of propafenone in subjects with pre-existing excito-conduction disorders].
Rizzo A; Fiorilli R; Lisanti P
G Ital Cardiol; 1984 May; 14(5):377-8. PubMed ID: 6468820
[TBL] [Abstract][Full Text] [Related]
13. The electrophysiologic effects of propafenone hydrochloride in the neonatal canine.
Villafane J; Gelband H; Xu H; McCormack J; Stolfi A; Pickoff AS
Pediatr Res; 1987 Jul; 22(1):50-4. PubMed ID: 3627871
[TBL] [Abstract][Full Text] [Related]
14. Effects of pilsicainide on systemic hemodynamics and cardiac function of anesthetized dogs.
Sakanashi M; Noguchi K; Matsuzaki T; Ojiri Y; Nakasone J; Itomine T; Higuchi M; Shiroma N
Cardioscience; 1993 Dec; 4(4):241-50. PubMed ID: 8298065
[TBL] [Abstract][Full Text] [Related]
15. The effects of the stereoisomers of propafenone and diprafenone in guinea-pig heart.
Groschner K; Lindner W; Schnedl H; Kukovetz WR
Br J Pharmacol; 1991 Mar; 102(3):669-74. PubMed ID: 1364837
[TBL] [Abstract][Full Text] [Related]
16. Cardiac electrophysiological effects of propafenone and its 5-hydroxylated metabolite in the conscious dog.
Boucher M; Chassaing C; Hamel JD; Poirier JM
Eur J Pharmacol; 1996 Nov; 315(2):171-7. PubMed ID: 8960881
[TBL] [Abstract][Full Text] [Related]
17. Antiarrhythmic, electrophysiologic and hemodynamic effects of ACC-9358.
Brown BS; Calzadilla SV; Diemer MJ; Hartman JC; Reynolds RD
J Pharmacol Exp Ther; 1987 Dec; 243(3):1225-34. PubMed ID: 3694532
[TBL] [Abstract][Full Text] [Related]
18. [Electrophysiologic effects of lorcainide (R 15889) in man].
Touboul P; Atallah G; Kirkorian G
Arch Mal Coeur Vaiss; 1981 Nov; 74(11):1333-40. PubMed ID: 6797372
[TBL] [Abstract][Full Text] [Related]
19. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872.
Bril A; Gout B; Bonhomme M; Landais L; Faivre JF; Linee P; Poyser RH; Ruffolo RR
J Pharmacol Exp Ther; 1996 Feb; 276(2):637-46. PubMed ID: 8632331
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiological characteristics of lorcainide, a new antiarrhythmic drug.
Solti F; Czakó E; Szatmáry L
Int J Clin Pharmacol Ther Toxicol; 1986 Jan; 24(1):26-9. PubMed ID: 3957486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
